Project description:To evaluate whether serum microRNAs can predict survival in nasopharyngeal carcinoma (NPC) patients, we analyzed the serum microRNA expression profiles in 8 NPC patients with shorter-survival time and 8 age- and gender-matched NPC patients with longer-survival time using microarray. We identified a four-microRNA signature can predict survival of NPC patients.
Project description:To evaluate whether serum microRNAs can predict survival in nasopharyngeal carcinoma (NPC) patients, we analyzed the serum microRNA expression profiles in 8 NPC patients with shorter-survival time and 8 age- and gender-matched NPC patients with longer-survival time using microarray. We identified a four-microRNA signature can predict survival of NPC patients. 8 serum samples from nasopharyngeal carcinoma patients with shorter-survival time and 8 serum samples from nasopharyngeal carinoma patients with longer-survival time
Project description:To evaluate whether serum micoRNAs can be biomarkers for diagnosis of type 1 diabetes mellitus, we analyzed the serum microRNA expression profiles in 6 patients with new-onset type 1 diabetes mellitus and 6 age- and gender-matched healthy controls. A difference was observed in 31 miRNAs between the patients and controls (fold change ≥ 2, P < 0.05)
Project description:Global microRNA expression profiling of serum were collected using Agilent miRNA microarrays (G4471A Human, Amadid 29297, Sanger 14) carrying 887 individual human miRNA probes. Two different sources of RNA were analyzed: serum from healthy controls (N=5) and patients with ovarian carcinoma (CA, n=5)